Navigation Links
U.S. FDA Approves Natazia(TM), a New Oral Contraceptive for the Prevention of Pregnancy
Date:5/6/2010

ghly effective in preventing pregnancy.  The PI calculation was based on criteria established by the FDA (pregnancies that occurred in women aged 18-35 years during cycles 1-13 (including pregnancies 7 days post-treatment).

The most common treatment-emergent adverse reactions (greater than or equal to 2%) were headache (including migraines) (13.2%), metrorrhagia and irregular menstruation (8.0%), breast pain, discomfort or tenderness (6.6%), nausea or vomiting (6.5%), acne (3.9%), and increased weight (2.8%).

For full prescribing information, please visit www.natazia.com or call 1.888.84.BAYER.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals operation of Bayer HealthCare LLC, a division of Bayer AG.  One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  In the United States, Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, Hematology/Neurology, and Oncology.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves New Combination Product Oral Contraceptive
2. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
3. FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
4. FDA Approves New Device for Adults with Severe and Persistent Asthma
5. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
6. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
7. FDA Approves First Totally Implanted Hearing System
8. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
9. FDA Approves Name Change for Heartburn Drug Kapidex
10. FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
11. FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015 BioElectronics Corporation (OTC Pink: ... Pain Therapy medical devices, announced today that its ... 7-day trial device has been published in the ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic ... an assessment.  Chronic pain is ...
(Date:8/4/2015)... 2015 Second Quarter 2015 Highlights: ... second quarter of 2014 , Net earnings attributable to ... million after adjustments , Diluted net earnings per share ... increased 15.2% to $99.4 million 2015 Outlook: ... range of 24.0% to 26.0%; Adjusted EBITDA margin remains between ...
(Date:8/4/2015)... Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today reported ... June 30, 2015 and updated its financial guidance for ... this morning, August 4, 2015, at 10:30 AM ET. ... by dialing (855) 582-8078. The conference ID is 90889796. ... revenues of $38.3 million, an increase of 118% as compared ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 31Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 32Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 33ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3
... First Presentation of Full Data Set from the TRIUMPH-1 Trial of ... ... SPRING, Md., May 21 United,Therapeutics Corporation (Nasdaq: UTHR ) ... seven presentations concerning,the treatment of pulmonary arterial hypertension (PAH) with treprostinil,were ...
... of Four HUMIRA Patients from CHARM Study in Remission at ... ... 21 Results from an,open-label extension study of two Abbott ... treated with,HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical,response, respectively, ...
Cached Medicine Technology:Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 3Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 5Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 2Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 4Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 5Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 7
(Date:8/4/2015)... ... August 05, 2015 , ... The National Association ... inductee into its VIP Woman of the Year Circle. She is recognized with ... organization exclusively for professional women, boasting more than 700,000 members and over 200 ...
(Date:8/4/2015)... ... August 04, 2015 , ... Statement by Paul Gionfriddo, President and CEO, Mental ... Mental Health Reform Act of 2015 by Senators Bill Cassidy and Christopher Murphy. ... in America. , “This legislation and H.R. 2646 [The Helping Families ...
(Date:8/4/2015)... ... August 04, 2015 , ... World Patent Marketing, a vertically ... a fitness invention that eliminates the need to have a partner or trainer ... industry is worth $30 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:8/4/2015)... ... August 04, 2015 , ... Atlantic Health System, one ... to Work® and Fortune among the top five in their list of the 20 ... Morristown, Overlook, Newton and Chilton Medical Centers, Goryeb Children’s Hospital and Atlantic Rehabilitation, is ...
(Date:8/4/2015)... Boca Raton, FL (PRWEB) , ... August 04, ... ... on-site diagnostic testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, ... momentum but has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at ...
Breaking Medicine News(10 mins):Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 3Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 4Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3
... March 11 CoreObjects is proud to announce ... Award" for their role in helping launch a product ... from diabetes. CoreObjects and their customer Piramal Healthcare shared ... the concept and development of the HbA1c Blood Sugar ...
... this week,s issue of the Journal of the American ... he and other physicians who worked in Haiti after the ... the face of a crushing wave of patients and inadequate ... the essay that the team of Johns Hopkins physicians that ...
... to the local store can end in getting lost, hurt, ... people with failing memories often keep driving, but a study ... even on familiar streets -- may be greater than once ... safe period behind the wheel because the disease is unpredictable, ...
... ... a Science of Consciousness" will be held April 22-23, 2010 in Madison, WI. , ... Madison, WI (PRWEB) March 11, 2010 ... Mirror: Toward a Science of Consciousness” will be held April 22-23, 2010 in Madison, WI. ...
... COLUMBUS, Ohio Cancer cells in rapidly growing brain ... die. When energy levels are high, tumor cells grow ... less and migrate more., Researchers at the Ohio State ... Richard J. Solove Research Institute have discovered the switch ...
... explaining to lawyers how hair alcohol testing works. , ... , , ... ... Care application orders increased by 46% ...
Cached Medicine News:Health News:CoreObjects Receives Project Management Institutes 'Excellence Award' for Diabetes Contribution 2Health News:Hopkins doctor/disaster expert says resource problems in Haiti required ethical decision-making 2Health News:Driving With Early Alzheimer's May Be Ill-Advised 2Health News:Driving With Early Alzheimer's May Be Ill-Advised 3Health News:"Consciousness" at 9th Annual International Bioethics Forum in Madison, Wisconsin 2Health News:Researchers discover brain tumor's 'grow-or-go' switch 2Health News:Researchers discover brain tumor's 'grow-or-go' switch 3Health News:Hair Alcohol Test Kit to Help in Third of Care Cases 2Health News:Hair Alcohol Test Kit to Help in Third of Care Cases 3
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Bipolar Atrial "J" Lead...
Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: